Atrion (NASDAQ:ATRI) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.
NASDAQ:ATRI opened at $657.85 on Friday. Atrion has a 52-week low of $516.85 and a 52-week high of $694.25. The firm has a market cap of $1.18 billion, a P/E ratio of 34.99 and a beta of 0.64.
Several large investors have recently added to or reduced their stakes in ATRI. Xact Kapitalforvaltning AB purchased a new position in Atrion during the first quarter worth about $248,000. Principal Financial Group Inc. purchased a new position in Atrion during the first quarter worth about $249,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp purchased a new position in Atrion during the second quarter worth about $240,000. Victory Capital Management Inc. grew its position in Atrion by 28.4% during the first quarter. Victory Capital Management Inc. now owns 438 shares of the medical instruments supplier’s stock worth $277,000 after buying an additional 97 shares in the last quarter. Finally, Chevy Chase Trust Holdings Inc. purchased a new position in Atrion during the second quarter worth about $300,000. Institutional investors own 61.98% of the company’s stock.
Atrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.